BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Argus Health
Novartis
Express Scripts
Queensland Health
Boehringer Ingelheim
Cantor Fitzgerald
Healthtrust
QuintilesIMS
Medtronic

Generated: January 20, 2018

DrugPatentWatch Database Preview

Sunovion Pharms Inc Company Profile

« Back to Dashboard

Summary for Sunovion Pharms Inc
International Patents:496
US Patents:30
Tradenames:7
Ingredients:7
NDAs:7

Drugs and US Patents for Sunovion Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-001 Oct 28, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-005 Jul 12, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-004 Apr 26, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sunovion Pharms Inc UTIBRON glycopyrrolate ; indacaterol maleate POWDER;INHALATION 207930-001 Oct 29, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-004 Nov 8, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-001 Nov 8, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-005 Jul 12, 2013 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-004 Nov 8, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sunovion Pharms Inc UTIBRON glycopyrrolate ; indacaterol maleate POWDER;INHALATION 207930-001 Oct 29, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Sunovion Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-002 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc UTIBRON glycopyrrolate ; indacaterol maleate POWDER;INHALATION 207930-001 Oct 29, 2015 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-002 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-001 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-003 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-002 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-001 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-001 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-002 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SUNOVION PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg ➤ Subscribe 10/28/2014
➤ Subscribe Tablets 1 mg, 2 mg and 3 mg ➤ Subscribe 12/15/2008

Non-Orange Book US Patents for Sunovion Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,884,794 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets ➤ Subscribe
8,182,791 Formulations for use in inhaler devices ➤ Subscribe
5,780,632 Imide derivatives and their production and use ➤ Subscribe
7,541,022 Pharmaceutical formulations for dry powder inhalers ➤ Subscribe
8,288,532 Asymmetric catalytic reduction of oxcarbazepine ➤ Subscribe
9,566,239 Pharmaceutical formulations for dry powder inhalers ➤ Subscribe
9,351,928 Method of making particles for use in a pharmaceutical composition ➤ Subscribe
8,871,274 Pharmaceutical formulations for dry powder inhalers ➤ Subscribe
8,932,635 Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation ➤ Subscribe
9,585,839 Particles for use in a pharmaceutical composition ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Sunovion Pharms Inc Drugs

Supplementary Protection Certificates for Sunovion Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
13/014 Ireland ➤ Subscribe PRODUCT NAME: GLYCOPYRRONIUM OR A SALT THEREOF; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928
2014000025 Germany ➤ Subscribe PRODUCT NAME: GLYCOPYRRONIUM ODER EIN SALZ ODER DERIVAT HIERVON (KOMPONENTE 1) UND INDACATEROL ODER EIN DERIVAT HIERVON ODER EIN SALZ VON INDACATEROL ODER EINEM DERIVAT HIERVON (KOMPONENTE 2); REGISTRATION NO/DATE: EU/1/13/862 20130919
550 Luxembourg ➤ Subscribe PRODUCT NAME: LURASIDONE, FACULTATIVEMENT SOUS FORME DE SA BASE LIBRE OU DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES. FIRST REGISTRATION: 20140327
166 Luxembourg ➤ Subscribe PRODUCT NAME: GLYCOPYRRONIUM OU UN DE SES SELS
90057-5 Sweden ➤ Subscribe PRODUCT NAME: LURASIDONE, OPTIONALLY IN THE FORM OF LURASIDONE HYDROCHLORIDE; REG. NO/DATE: EU/1/14/913 20140327
393 Luxembourg ➤ Subscribe PRODUCT NAME: GLYCOPYRRONIUM OU UN SEL DE CELUI-CI, PLUS PARTICULIEREMENT LE SEL BROMURE, COMBINE A INDACATEROL OU UN SEL DE CELUI-CI, PLUS PARTICULIEREMENT LE SEL MALEATE. FIRST REGISTRATION: 20130923
3 Finland ➤ Subscribe
2013000029 Germany ➤ Subscribe PRODUCT NAME: GLYKOPYRRONIUM ODER EIN SALZ ODER DERIVAT HIERVON; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928
651 Luxembourg ➤ Subscribe 91651, EXPIRES: 20241130
C027/2009 Ireland ➤ Subscribe SPC027/2009: 20091119, EXPIRES: 20210627
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Daiichi Sankyo
Colorcon
Harvard Business School
Express Scripts
US Department of Justice
Chinese Patent Office
Teva
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot